Program
Clascoterone
Also written as “Winlevi (clascoterone) 1% cream”, “CB-03-01 cream, 1%” and “Clascoterone 5% solution”.
Its studies are mostly in Acne Vulgaris · Alopecia, led by 4 companies.
Drug pageClascoterone: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cassiopea SpAits history only | 70 open or running | phase 3since Nov 17, 2015 | Nov 17, 2015 | none ahead |
| Sun Pharmaceutical Industries | 61 open or running | phase 4since Mar 11, 2024 | Mar 11, 2024 | none ahead |
| 3SBioits history only | 32 open or running | phase 3since Apr 30, 2024 | Apr 30, 2024 | Aug 7, 2028phase 3 · NCT07457294 |
| Intrepid Therapeuticsits history only | 30 open or running | phase 2since Jun 27, 2012 | Jun 27, 2012 | none ahead |
Also a collaborator on its studies: Canfield Scientific and ICON Clinical Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sun Pharmaceutical Industries only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2018Named clascoteroneINNProposed as its International Nonproprietary Name in WHO's List 120
- Mar 11, 2024First studies: 2 phase 4 studies in Acne VulgarisFirst studyNCT06336629, NCT06336603
- May 10, 20244 phase 4 studies in Acne VulgarisNCT06425900, NCT06415305, NCT06415292 and 1 more
TargetBeta
“Androgen Receptor antagonist”ChEMBL 37, by rule
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enzalutamiderule | Astellas Pharma | phase 4 | 69 |
| apalutamiderule | Johnson & Johnson | phase 4 | 31 |
| darolutamiderule | Bayer | phase 4 | 26 |
| ostarinerule | gtx | phase 3 | 15 |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 13 |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 5 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 6 |
| luxdegalutamide | Novartis | phase 2 | 3 |
| luxdegalutamide | Novartis | phase 2 | 2 |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 1 |
Studies
All 6 Sun Pharmaceutical Industries leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06425900Acne Vulgaris · United States | 4 | Active, not recruiting | Mar 2026 | 10 |
| NCT06415305Acne Vulgaris · United States | 4 | Completed | Apr 17, 2024 | 10 |
| NCT06415292Acne Vulgaris · United States | 4 | Completed | Dec 16, 2023 | 50 |
| NCT06415279Acne Vulgaris · United States | 4 | Completed | Feb 12, 2025 | 40 |
| NCT06336629Acne Vulgaris · United States | 4 | Completed | Jul 10, 2024 | 10 |
| NCT06336603Acne Vulgaris · United States | 4 | Completed | Oct 29, 2024 | 20 |
How it is read
Names in the registry
- “Winlevi (clascoterone) 1% cream”, 3 entries
- “CB-03-01 cream, 1%”, 3 entries
- “Clascoterone 5% solution”, 2 entries
- “cortexolone 17α-propionate”, 2 entries
- “CB-03-01”, 2 entries
Conditions, from the studies’ own filings
- Acne Vulgaris, 15 studies
- Alopecia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.